News
PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on
developing therapeutics based upon the use of human cells and their
derivatives, announced today progress regarding human trials on its
product, UMK-121.
Proteonomix has been informed that patient screening has commenced at
the University of
Miami.(http://ctt.marketwire.com/?release856844&id1315555&type1&urlhttp%3a%2f%2...)
Proteonomix, CTO, Steven Byle stated that "We are excited to see our
years of hard work and research investment coming to fruition. We at
Proteonomix consider ourselves fortunate to be involved in a business
that has the opportunity to try and help people in such dire need. We
look forward to monitoring the trials going forward."
It should be noted that effective March 7, 2012, a new FDA
rule(http://ctt.marketwire.com/?release856844&id1315558&type1&urlhttp%3a%2f%2...)
will require that informed consent documents state that the clinical
trial has been or will be registered and the results will be published
in the National Institutes of Health/National Library of Medicine
clinical trials database
(www.clinicaltrials.gov(http://ctt.marketwire.com/?release856844&id1315561&type1&urlhttp%3a%2f%2...)).
After such date, it is anticipated that any person may find out
additional information and follow the progress of these human trials
on this government informational site.
About Proteonomix, Inc.:
Proteonomix is a biotechnology company focused on developing
therapeutics based upon the use of human cells and their derivatives.
The Proteonomix Family of companies includes Proteoderm, StromaCel,
PRTMI and THOR Biopharma. Proteoderm, Inc. is a wholly owned
subsidiary that has developed an anti-aging line of skin care
products. StromaCel, Inc. develops therapeutic modalities for the
treatment of Cardiovascular Disease (CVD). Proteonomix Regenerative
Translational Medicine Institute, Inc. ("PRTMI") intends to focus on
the translation of promising research in stem cell biology and
cellular therapy to clinical applications of regenerative medicine.
Proteonomix intends to create and dedicate a subsidiary to each of its
technologies. Please also visit
http://www.proteonomix.com/(http://ctt.marketwire.com/?release856844&id1315564&type1&urlhttp%3a%2f%2...),
http://www.proteoderm.com/(http://ctt.marketwire.com/?release856844&id1315567&type1&urlhttp%3a%2f%2...),
http://www.otcqb.com/(http://ctt.marketwire.com/?release856844&id1315570&type1&urlhttp%3a%2f%2...)
and
http://www.sec.gov/(http://ctt.marketwire.com/?release856844&id1315573&type1&urlhttp%3a%2f%2...).
Forward-looking statements:
Certain statements contained herein are "forward-looking statements"
(as defined in the Private Securities Litigation Reform Act of 1995).
Proteonomix, Inc. cautions that statements made in this press release
constitute forward-looking statements and makes no guarantee of future
performance. Actual results or developments may differ materially from
projections. Forward-looking statements are based on estimates and
opinions of management at the time statements are made.
Add to
Digg(http://digg.com/submit?phase2&urlhttp://www2.marketwire.com/mw/release_h...)Bookmark
with
del.icio.us(http://del.icio.us/post?v4&noui&jumpclose&urlhttp://www2.marketwire.com/...)Add
to
Newsvine(http://www.newsvine.com/_tools/seed&save?uhttp://www2.marketwire.com/mw/...)
